PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
67.73 USD
+0.73 (+1.09%)
67.73 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to PBH. PBH was compared to 191 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- PBH had positive earnings in the past year.
- PBH had a positive operating cash flow in the past year.
- Of the past 5 years PBH 4 years were profitable.
- PBH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of PBH (5.83%) is better than 86.91% of its industry peers.
- With an excellent Return On Equity value of 11.00%, PBH belongs to the best of the industry, outperforming 85.86% of the companies in the same industry.
- The Return On Invested Capital of PBH (7.88%) is better than 85.86% of its industry peers.
- PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is below the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
- PBH has a Profit Margin of 18.09%. This is amongst the best in the industry. PBH outperforms 90.05% of its industry peers.
- PBH's Profit Margin has improved in the last couple of years.
- PBH's Operating Margin of 31.00% is amongst the best of the industry. PBH outperforms 94.24% of its industry peers.
- PBH's Operating Margin has been stable in the last couple of years.
- PBH has a better Gross Margin (56.10%) than 68.06% of its industry peers.
- In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
- PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for PBH has been reduced compared to 1 year ago.
- PBH has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 2.64 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of PBH (2.64) is better than 63.35% of its industry peers.
- PBH has a debt to FCF ratio of 3.97. This is a good value and a sign of high solvency as PBH would need 3.97 years to pay back of all of its debts.
- PBH has a better Debt to FCF ratio (3.97) than 86.39% of its industry peers.
- PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.55, PBH is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.64 |
ROIC/WACC0.88
WACC8.91%
2.3 Liquidity
- A Current Ratio of 3.70 indicates that PBH has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 3.70, PBH is in line with its industry, outperforming 57.59% of the companies in the same industry.
- A Quick Ratio of 2.51 indicates that PBH has no problem at all paying its short term obligations.
- PBH has a Quick ratio (2.51) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
- PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.15%, which is quite good.
- Measured over the past years, PBH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.88% on average per year.
- Looking at the last year, PBH shows a decrease in Revenue. The Revenue has decreased by -0.02% in the last year.
- The Revenue has been growing slightly by 3.39% on average over the past years.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
- Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 4.13% on average per year.
- Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 1.15% on average per year.
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 14.85, which indicates a correct valuation of PBH.
- 86.91% of the companies in the same industry are more expensive than PBH, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 27.32. PBH is valued slightly cheaper when compared to this.
- The Price/Forward Earnings ratio is 13.83, which indicates a correct valuation of PBH.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 84.29% of the companies listed in the same industry.
- PBH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.85 | ||
| Fwd PE | 13.83 |
4.2 Price Multiples
- 86.39% of the companies in the same industry are more expensive than PBH, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, PBH is valued cheaply inside the industry as 89.01% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.75 | ||
| EV/EBITDA | 11.02 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
- PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)9.05
PEG (5Y)1.67
EPS Next 2Y3.96%
EPS Next 3Y3.41%
5. Dividend
5.1 Amount
- PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
67.73
+0.73 (+1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-05 2026-02-05/bmo
Inst Owners108.83%
Inst Owner Change1.66%
Ins Owners1.31%
Ins Owner Change0.82%
Market Cap3.26B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price Target79.05 (16.71%)
Short Float %4.28%
Short Ratio4.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)0%
PT rev (3m)-7.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.36%
EPS NY rev (1m)0%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.85 | ||
| Fwd PE | 13.83 | ||
| P/S | 2.93 | ||
| P/FCF | 12.75 | ||
| P/OCF | 12.36 | ||
| P/B | 1.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.02 |
EPS(TTM)4.56
EY6.73%
EPS(NY)4.9
Fwd EY7.23%
FCF(TTM)5.31
FCFY7.84%
OCF(TTM)5.48
OCFY8.09%
SpS23.1
BVpS37.96
TBVpS-20.68
PEG (NY)9.05
PEG (5Y)1.67
Graham Number62.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.64 |
F-Score7
WACC8.91%
ROIC/WACC0.88
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y3.05%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
What is the profitability of PBH stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.64% in the next year.